Navigation Links
Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
Date:11/3/2008

Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of submission for approval and launch of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of whic
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
2. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
3. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
4. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
5. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
6. Rosetta Genomics Reports Second Quarter 2008 Financial Results
7. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
8. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
9. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
10. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
11. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... , , FRAMINGHAM, ... HTWR ) (ASX: HIN) today confirmed that trading ... Exchange ("ASX") was temporarily suspended for the reasons stated below. ... NASDAQ is also temporarily suspended. Based on discussions with ...
... , ANNAPOLIS, Md., Sept. 1 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, announced today that ... Investment Conference 2009. The Company is scheduled to present ... the Hubbard Salon (5th Floor) at the New York Palace ...
... , , DALLAS, Sept. 1 ... (OTC Bulletin Board : ACCP) announced today that ... be held September 9-11, 2009 at the New York Palace Hotel in New ... to speak on Friday, September 11, 2009 at 10:50 am EDT in the ...
Cached Biology Technology:HeartWare International, Inc. Temporary Suspension of Trading 2HeartWare International, Inc. Temporary Suspension of Trading 3Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 3
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... 2009 / b3c newswire / - DuoCort ... rare and life threatening disease adrenal insufficiency. The release ... hydrocortisone dosing closely resembles the physiological secretion pattern. The ... Endocrinology, a leading scientific journal for endocrinology. ...
... for the organism, and this is true even for the ... of present marine mammals initiated their return to the oceans, ... Dr. Michael Berenbrink and his colleagues at Liverpool University have ... to the muscles during locomotion, has been modified in seals ...
... pregnancy or in previous pregnancies can predict the,likelihood ... according to research carried out by an,international group ... to predict more easily which women might need ... enabling new research to improve clinical management of ...
Cached Biology News:DuoCort: New chronotherapy for adrenal insufficiency 2DuoCort: New chronotherapy for adrenal insufficiency 3Natural-born divers and the molecular traces of evolution 2Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies 2Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies 3
Mouse monoclonal antibody to FMN2 - formin 2...
...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... (KLF15) KLF15 is a Cys2-His2 zinc ... in the liver, kidneys, heart, and skeletal ... Polyclonal antibody produced in rabbits immunized with ... of human KLF15 with an internal ID ...
Biology Products: